GlassScriptPhysician profile
Todd Richard Simpson
NPI 1215051628
$2,539.92
in general payments reported to CMS, 2019-2025
18 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $182 · 2021: $375 · 2022: $535 · 2023: $506 · 2024: $369 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.34 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $910.59 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $257.55 | 2024-2025 | Voquezna |
| Currax Pharmaceuticals LLC | $248.76 | 2021-2025 | Contrave, Nexletol, Onzetra Xsail |
| Abbvie INC. | $239.71 | 2021-2023 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $188.68 | 2020-2024 | Zepbound, Mounjaro |
| Upsher-Smith Laboratories LLC | $130.06 | 2019 | |
| Pfizer INC. | $114.28 | 2019-2025 | |
| Astellas Pharma US INC | $94.95 | 2021 | |
| Gilead Sciences, INC. | $80.43 | 2019 | |
| Braeburn INC. | $48.43 | 2024-2025 | Brixadi |
| Astrazeneca Pharmaceuticals LP | $44.13 | 2020 | |
| Indivior INC. | $44.11 | 2021-2023 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.92 | 2021 | |
| Kerecis Limited | $31.17 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Allergan, INC. | $22.38 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $18.42 | 2022 | |
| Merz Pharmaceuticals, LLC | $15.27 | 2021 | |
| Amgen INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.